The objective of the Hawaii Minority-Based Community Clinical Oncology Program (MBCCOP) is to reduce cancer incidence, morbidity, and mortality in Hawaii by: a. providing support to expand clinical research in the state of Hawaii, a multiethnic population with a majority of non-Caucasian cancer patients; b. bringing the advantages of state-of-the-art treatment and cancer prevention and control research to minority individuals in their own communities; c. increasing the involvement of primary health care providers and other specialists in cancer prevention and control studies; d. strengthening the operational base that currently exists to extend cancer prevention and control research in this population; e. examining specific trials-related issues such as recruitment and adherence as a function of ethnocultural characteristics of Hawaii's population. The Cancer Research Center of Hawaii will serve as the administrative headquarters for the MBCCOP to direct recruitment, accrual, and data management for NCI-approved cancer treatment and control clinical trials. The Center and its personnel have extensive previous experience in developing and conducting clinical trials research. The Southwest Oncology Group, M.D. Anderson, and the Pediatric Oncology Group are the Hawaii MBCCOP research bases. The participating physicians include all oncologists on the island of Oahu, as well as professionals from other medical and non-medical specialties. All major Oahu hospitals will serve as component institutions. The MBCCOP will allow the people of Hawaii, 80% of whom are Asian and Pacific Islanders, to benefit from access to state- of-the-art cancer treatment and control interventions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
1U10CA063844-01
Application #
2105954
Study Section
Special Emphasis Panel (SRC (86))
Project Start
1994-08-01
Project End
1997-07-31
Budget Start
1994-08-01
Budget End
1995-07-31
Support Year
1
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of Hawaii
Department
Type
Organized Research Units
DUNS #
121911077
City
Honolulu
State
HI
Country
United States
Zip Code
96822
Sparano, Joseph A; Gray, Robert J; Makower, Della F et al. (2018) Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 379:111-121
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068
Ramanathan, Ramesh K; McDonough, Shannon L; Kennecke, Hagen F et al. (2015) Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005). Cancer 121:2193-7
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Yu, Evan Y; Li, Hongli; Higano, Celestia S et al. (2015) SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 33:1601-8
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
El-Khoueiry, A B; Rankin, C; Siegel, A B et al. (2014) S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma. Br J Cancer 110:882-7
Goldkorn, Amir; Ely, Benjamin; Quinn, David I et al. (2014) Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32:1136-42
Loprinzi, Charles L; Qin, Rui; Dakhil, Shaker R et al. (2014) Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol 32:997-1005

Showing the most recent 10 out of 115 publications